BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

...Inex Innovations Exchange Pte. Ltd. and Nova Satra Dx Pte. Ltd. will merge to form Inex...
...for Health and Care Excellence (NICE) Swedish Orphan Biovitrum AB Glucagon receptor (GCGR) Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Inex Innovate Inex...
BioCentury | Apr 15, 2013
Clinical News

Inex preclinical data

Inex Pharmaceuticals Corp. (TSE:IEX), Vancouver, B.C. Product: Transmembrane carrier system (TCS) Use: Gene therapy vector IEX presented results demonstrating the ability of its system, a combination of lipids and polymers, to protect encapsulated DNA from...
BioCentury | Apr 15, 2013
Company News

Inex Pharmaceuticals Corp other research news

...it has evidence that the TCS can be administered repeatedly without eliciting an immune response. Inex...
BioCentury | Aug 20, 2012
Product Development

Clawing towards approval

...Researchers at the University of British Columbia discovered Marqibo, which was licensed in 1992 to Inex Pharmaceuticals Corp....
...approvable letter soon after (see BioCentury, Dec. 6, 2004) . Over the next 18 months, Inex...
...rights to Marqibo and two preclinical chemotherapeutics formulated with next-generation liposomal delivery technology. In exchange, Inex...
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...At a 2004 ODAC meeting convened to discuss an application from Enzon Pharmaceuticals Corp. and Inex...
BioCentury | Sep 13, 2010
Company News

HealthLinx, Inex Innovations Exchange, Quest Laboratories, Medison sales and marketing update

...Inex launched HealthLinx's OvPlex ovarian cancer diagnostic in Singapore. Inex has exclusive rights under a 2009...
...that measures five biomarkers in Singapore, Malaysia, India Thailand, Indonesia and Vietnam for 10 years. Inex...
...responsible for regulatory approval. HealthLinx is eligible for double-digit royalties. HealthLinx Ltd. (ASX:HTX), Melbourne, Australia Inex...
BioCentury | Jun 14, 2010
Clinical News

Marqibo vincristine: Final Phase II data

...dataset (see BioCentury, Dec. 14, 2009). Hana has exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Dec 14, 2009
Clinical News

Marqibo vincristine: Phase II data

...in March (see BioCentury, March 9). Hana has exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Dec 14, 2009
Clinical News

Marqibo vincristine: Phase II expanded

...to collect a more robust pharmacokinetic dataset. Hana received exclusive rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Aug 17, 2009
Clinical News

Marqibo vincristine: Phase II

...trial evaluating Marqibo given once weekly. Hana received exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
Items per page:
1 - 10 of 199
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

...Inex Innovations Exchange Pte. Ltd. and Nova Satra Dx Pte. Ltd. will merge to form Inex...
...for Health and Care Excellence (NICE) Swedish Orphan Biovitrum AB Glucagon receptor (GCGR) Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Inex Innovate Inex...
BioCentury | Apr 15, 2013
Clinical News

Inex preclinical data

Inex Pharmaceuticals Corp. (TSE:IEX), Vancouver, B.C. Product: Transmembrane carrier system (TCS) Use: Gene therapy vector IEX presented results demonstrating the ability of its system, a combination of lipids and polymers, to protect encapsulated DNA from...
BioCentury | Apr 15, 2013
Company News

Inex Pharmaceuticals Corp other research news

...it has evidence that the TCS can be administered repeatedly without eliciting an immune response. Inex...
BioCentury | Aug 20, 2012
Product Development

Clawing towards approval

...Researchers at the University of British Columbia discovered Marqibo, which was licensed in 1992 to Inex Pharmaceuticals Corp....
...approvable letter soon after (see BioCentury, Dec. 6, 2004) . Over the next 18 months, Inex...
...rights to Marqibo and two preclinical chemotherapeutics formulated with next-generation liposomal delivery technology. In exchange, Inex...
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...At a 2004 ODAC meeting convened to discuss an application from Enzon Pharmaceuticals Corp. and Inex...
BioCentury | Sep 13, 2010
Company News

HealthLinx, Inex Innovations Exchange, Quest Laboratories, Medison sales and marketing update

...Inex launched HealthLinx's OvPlex ovarian cancer diagnostic in Singapore. Inex has exclusive rights under a 2009...
...that measures five biomarkers in Singapore, Malaysia, India Thailand, Indonesia and Vietnam for 10 years. Inex...
...responsible for regulatory approval. HealthLinx is eligible for double-digit royalties. HealthLinx Ltd. (ASX:HTX), Melbourne, Australia Inex...
BioCentury | Jun 14, 2010
Clinical News

Marqibo vincristine: Final Phase II data

...dataset (see BioCentury, Dec. 14, 2009). Hana has exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Dec 14, 2009
Clinical News

Marqibo vincristine: Phase II data

...in March (see BioCentury, March 9). Hana has exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Dec 14, 2009
Clinical News

Marqibo vincristine: Phase II expanded

...to collect a more robust pharmacokinetic dataset. Hana received exclusive rights to the compound from Inex Pharmaceuticals Corp....
BioCentury | Aug 17, 2009
Clinical News

Marqibo vincristine: Phase II

...trial evaluating Marqibo given once weekly. Hana received exclusive, worldwide rights to the compound from Inex Pharmaceuticals Corp....
Items per page:
1 - 10 of 199